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were	more	 likely	 to	 be	 female,	 lack	 social	 support,	 have	 active	 disease,	 be	 taking	
corticosteroids	 but	 not	 TNF‐alpha	 inhibitors	 and	 exhibit	 less	 positive	 emotional	
recognition	 bias.	 On	 multivariable	 regression	 analysis,	 depression	 was	 associated	
independently	 with	 lack	 of	 social	 support	 (unstandardized	 regression	 coefficient	
(B) =	−1.40,	P	=	0.02)	and	increased	disease	activity	(B	=	1.29,	P	=	0.03).	Causal	steps
analysis was consistent with less positive emotional recognition bias partially mediat‐
ing	the	effects	of	disease	activity	on	depression.
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1  | INTRODUC TION
Depression	 affects	 14%‐27%	 patients	 with	 inflammatory	 bowel	
disease	 (IBD),	 which	 is	 approximately	 2‐3	 times	 the	 prevalence	
in	 people	without	 IBD.1‐3	Depression	 in	 IBD	 is	 important	 because	
it is associated with more gastrointestinal symptoms independ‐
ent	of	disease	 severity,4	worse	health‐related	quality	of	 life,5‐8 in‐
creased	 healthcare	 utilisation,9‐11 and possibly relapses in disease 
activity.12‐16	Depression	is	associated	with	a	number	of	sociodemo‐





ical	 populations	 have	 shown	 that	 inflammation	 is	 associated	 with	
depression.22‐24	 Also,	 controlled,	 experimental	 studies	 in	 healthy	
individuals	have	shown	that	acute	 inflammation	causes	short	 term	
increases in depressive symptoms.25,26	Among	people	with	severe	
Crohn's	 disease,	 treatment	 with	 the	 anti‐TNF‐alpha	 drugs	 inflix‐
imab and adalimumab has been associated with a rapid reduction 
in	 depression,	 not	 attributable	 solely	 to	 reductions	 in	 clinical	 dis‐





to	 the	 development	 of	 depression,	 though	 their	 association	 with	
chronic	inflammation	in	people	with	IBD	has	not	been	investigated	
previously.31,32
We	 conducted	 a	 cross‐sectional	 study	 among	 hospital	 out‐




We	 tested	 the	 following	 hypotheses	 among	 outpatients	 with	
IBD:
1. Depression	 would	 be	 independently	 predicted	 by	 socio‐demo‐
graphic	 characteristics	 (age,	 sex,	 socioeconomic	 status,	 social
support),	 medical	 characteristics	 (type	 of	 IBD,	 IBD	 activity),
and psychological characteristics (negative biases in emotional
processing)
2. Negative	 biases	 in	 emotional	 processing	would	mediate	 the	 ef‐
fects	of	disease	activity	on	depression











would	 provide	 ≥80%	 power	 to	 detect	 bivariate	 correlations	 of	 at	
least r	 =	 0.3	 between	measures	 of	 emotional	 processing,	markers	




ticipant per independent variable added.33
2.2 | Baseline assessments











The	 frequency of depressive symptoms	 in	 the	 previous	 2	weeks	
was	assessed	using	9‐item	Patient	Health	Questionnaire,	PHQ‐9.34 
Scores	could	range	from	0	to	27,	with	higher	scores	indicating	worse	
depression.	 A	 cut‐off	 score	 of	 ≥10	 indicates	moderate	 depressive	
Key Points
• Depression	 is	 common	 in	 people	 with	 inflammatory
bowel	disease	(IBD),	but	the	actual	causes	of	depression
in	this	group	are	unknown.





ease activity and less positive biases in emotional rec‐





Assessment,	 GAD‐7,35 perceived social support was assessed using 
the	 seven	 item	ENRICHD	 social	 support	 inventory36‐38 and recent 
life stresses	 were	 assessed	 using	 the	 12‐item	 List	 of	 Threatening	
Experiences	questionnaire.39	The	EQ‐5D	questionnaire	was	used	to	
assess generic health‐related quality of life40	and	 the	10‐item,	Short	
Inflammatory	Bowel	Disease	questionnaire	was	used	to	record	dis‐
ease‐specific health‐related quality of life.41,42
Questionnaire	 assessments	were	 completed	 in	 clinic	 following	
recruitment,	though	participants	could	take	them	home	to	complete,	
if	preferred.
2.2.2 | Data extracted from medical records
We	 recorded	 demographic	 data,	 smoking	 status,	 age	 at	 diagnosis,	






tion	of	medical	 records.	Two	experienced	clinicians	 (JG,	NH)	 inde‐





2.2.3 | Computerized assessment of 
emotional processing
We	selected	specific	tests	from	a	validated	computerized	neuropsy‐











in	 the	 center	 of	 the	 screen	 (random	 duration	 between	 1500	 and	
2500	milliseconds),	followed	by	an	image	of	eyes	(250	milliseconds).	
The	image	was	 immediately	replaced	by	a	grey	mask	(150	millisec‐








2.2.5 | Emotional memory recognition task
The	 Emotional	Memory	 Recognition	 Task	 (EMRT)	 was	 presented	
in	 two	 parts.	During	 the	 first	 phase	 (encoding)	 participants	were	
shown	 30	 photographic	 scenes	 without	 people	 (10	 positive,	 10	
negative	and	10	neutral).	In	each	trial	a	fixation	cross	was	displayed	































Next,	 in	 the	 transfer	 phase	 there	were	 48	 trials	where	 all	 possi‐
ble	pairs	of	circles	were	presented.	Participants	were	instructed	to	
continue	to	select	their	preferred	circle,	although	no	feedback	was	
provided in this phase.
Performance	on	the	RLT	is	reported	using	learning	rate	(ie,	how	






















(latex)	 high	 sensitive,	 particle	 enhanced	 immunoturbidimetric	
assay	 on	 the	 702	module	 of	 a	 Roche/Hitachi	 cobas	 8000	 auto‐
mated	 analyzer.	 The	 lower	 detection	 limit	 for	 hs‐CRP	 using	 this	
system	was	 0.15	mg/L.	One	 subject	 had	 levels	 below	 this	 lower	
limit	 of	 detection	 (<0.15	mg/L)	 and,	 for	 the	purposes	of	 analysis	
hs‐CRP	as	a	continuous	variable,	levels	for	this	individual	were	as‐




Preliminary	 examination	of	 the	 continuous	 variables	 using	1‐sam‐
ple	Kolmogorov‐Smirnov	tests	revealed	that	our	a	priori	assumption	
that	key	variables	would	be	normally	distributed	was	 incorrect.	 In	
fact,	 the	 vast	 majority	 of	 variables	 were	 non‐parametrically	 dis‐





logical	 variables	 according	 to	 depression	 status	 were	 examined	
using	 the	 Mann	Whitney	U	 test	 for	 continuous	 data.	 Chi‐square	
tests	were	 used	 to	 compare	 categorical	 data,	 with	 Fisher's	 Exact	
test	 used	where	 contingency	 tables	 included	 cells	 with	 expected	
frequencies	<5.
To	 identify	 variables	 independently	 associated	 with	 depres‐
sion,	multivariable	 logistic	 regression	 analysis	was	 conducted	 that	
included	 the	 following	 independent	 variables:	 Block	 1:	 age,	 sex,	
socioeconomic	 status,	 social	 support,	 Block	 2:	 IBD	 type	 (Crohn's	
Disease,	Ulcerative	Colitis,	Unclassified)	and	IBD	activity	(Active	vs	
Inactive	 IBD),	 Block	 3:	 psychological	 characteristics	 (bias	 in	 emo‐
tional	processing).	Due	to	the	highly	non‐parametric	distribution	of	
independent	variables,	for	the	purposes	of	the	regression	analyses	













1. Disease	activity	predicted	depression	 (the	 total,	unadjusted,	ef‐
fect	of	predictor	on	outcome,	path c’).
2. Disease activity predicted emotional recognition bias (the direct
effect	of	predictor	on	mediator,	path a).
3. Emotional	recognition	bias	significantly	predicted	depression	in	a
model that also included disease activity (path b,	the	direct	effect
of	mediator	on	outcome).
4. The	regression	coefficient	of	disease	activity	on	depression	in	the
model that also included emotional recognition bias (path c,	 the
direct	effect	of	predictor	on	outcome)	was	smaller	than	the	coef‐
ficient	of	the	total	effect	(path c’).
If	 the	causal	 steps	approach	 indicated	 findings	consistent	with	
mediation,	a	bootstrapping	method	with	5000	samples	and	bias	cor‐






F I G U R E  1  Method	used	for	testing	mediation
3  | RESULTS
3.1 | Participant characteristics














less	 likely	 to	be	 taking	anti‐TNF	drugs	 (20%	vs	45.9%,	P	=	0.008).	
Participants with active disease had worse generic and disease 
specific	health‐related	quality	of	 life	 (EQ‐5D	 index	value	and	VAS;	
SIBDQ	Systemic,	Social,	Bowel	and	Emotional	domains	of	the	Short	
IBD	questionnaire,	all	P's	≤	0.005).
Overall participants showed a positive bias in emotion recog‐
nition	[median	emotional	recognition	bias	=	+15%	(IQR:	0.0‐30.0)]	
and	 a	 negative	 bias	 in	 emotional	 memory	 [median	 emotional	
memory	bias	=	−10%	(IQR	=	−30.0	to	0.0)].	Emotional	recognition	
bias	was	 less	positive	 in	people	with	active	disease	 [median	 rec‐
ognition	 bias	 +5%	 (IQR:	 −5.0	 to	 20.0)	 vs	 +15%	 (IQR:	 2.50‐35.0),	
Mann	Whitney,	 P	 =	 0.028],	 but	 was	 not	 significantly	 associated	
with	 hs‐CRP	 (Spearman's	 correlation	 coefficient	 (ρ)	 =	 −0.04,	
n	=	101,	P	=	0.73)	or	white	cell	count	(ρ	=	−0.01,	n	=	112,	P	=	0.91).	
Emotional	memory	 bias	 and	 learning	 rate	 (win	 or	 loss)	were	 not	
significantly	associated	with	disease	activity	or	markers	of	inflam‐
matory activity.
3.2 | Sociodemographic, IBD and psychological 
factors associated with depression
Of	the	120	participants	recruited,	105	returned	questionnaires,	of	
which	104	included	completed	depression	assessments.	There	were	
no	 significant	differences	with	 regards	 to	age,	 sex,	 socioeconomic	
status or disease activity between those 104 returning the depres‐
sion assessment and the 16 who did not.
Twenty‐six	participants	(25%)	were	depressed	(PHQ‐9	score	≥10).	
Sociodemographic,	 clinical	 and	 psychological	 factors	 that	 showed	
univariate	associations	with	depression	can	be	seen	 in	Table	2.	Of	
note,	those	with	depression	were	significantly	more	likely	to	be	fe‐







related to reward or loss.
Using	 multivariable	 logistic	 regression,	 the	 overall	 model	
was	 significant	 (Chi‐square	 =	 24.9,	 P	 =	 0.001,	 Cox	 and	 Snell	 R‐
square	=	0.22).	Within	 the	model,	 depression	was	 independently	
associated	with	 less	 social	 support	 [odds	 ratio	 (OR)	 =	 0.25	 (95%	
CI	 =	 0.08‐0.76),	P	 =	 0.02]	 and	 greater	 disease	 activity	 [OR	=	3.6	
(95%	CI	=	1.14‐11.60)	P	=	0.03)	(Table	3).	Age,	sex,	IMD	and	emo‐
tional	recognition	bias	[OR	=	0.39,	(95%	CI	=	0.12‐1.27),	P	=	0.12]	
did	not	make	any	significant	 independent	contribution	 to	 the	 full	
regression model.
Since	disease	 activity	 and	 emotional	 recognition	bias	 showed	
a	 significant	 univariate	 association	with	 each	 other,	we	 explored	
the	effect	of	removing	disease	activity	from	the	regression	model.	
When	 disease	 activity	was	 removed	 from	 the	model,	 the	 overall	
model	remained	significant	(Chi‐square	=	20.1,	P	=	0.003,	Cox	and	
Snell	 R‐square	 =	 0.182),	 and	 less	 positive	 emotional	 recognition	
bias	(B	=	−1.20,	SE	=	0.58,	P	=	0.04,	Exp	(B)	=	0.30)	and	less	social	
support	 (B	=	−1.31,	SE	=	0.55,	P	=	0.02,	Exp	 (B)	=	0.27)	were	the	
only	 variables	 to	make	 a	 significant	 independent	 contribution	 to	
the model.
Using	the	causal	steps	approach,	disease	activity	was	associated	
with emotional recognition bias (B	=	−0.93,	P	=	0.043)	and	both	dis‐
ease	activity	 (B	=	1.47,	P	=	0.003)	and	emotional	 recognition	bias	
(B	 =	 −1.27,	 P	 =	 0.019)	 predicted	 depression.	 The	 contribution	 of	
disease activity to the model decreased when emotional recogni‐
tion was added to the model (B	=	1.29,	P	=	0.012,	Figure	2),	con‐
sistent	with	 emotional	 recognition	partially	mediating	 the	 effects	








We	 found	 that	 depression	 affected	 25%	 of	 people	 with	 IBD	 and	
was	associated	with	a	wide	range	of	sociodemographic,	IBD‐related	
and	psychological	factors	including	less	positive	biases	in	emotional	
recognition.	 However,	 on	 multivariable	 analysis,	 depression	 was	
predicted	by	a	lack	of	social	support	and	greater	IBD	activity,	only.	
Causal	 steps	 analysis	 suggested	 that	 emotional	 recognition	 bias	
partially mediated the relationship between disease activity and de‐
pression,	as	we	hypothesized.
This	is	the	first	study	to	explore	links	between	disease	activity	





















Disease type Crohn's 68	(56.7)
UC 49	(40.8)
IBD‐U 3	(2.5)
Disease duration Years 9.2	(4.2‐15.2)
Age	at	diagnosis Years 29.9	(22.3‐43.6)

































































































TA B L E  1   (Continued)
TA B L E  2  Comparing	depressed	with	non‐depressed
Characteristic Depressed (N = 26) Non‐depressed (N = 78) Comparison
Socio‐demographic	factors
Age Years 42.5	(33.8‐50.8) 49.5	(35.0‐59.0) MW,	P	=	0.09
Sex Male 7	(26.9) 40	(51.3) χ2	(1)	=	4.7,	P	=	0.031
Ethnicity White	British 26	(100) 78	(100)
Socio‐economic IMD	decile 5.0	(4.0‐8.0) 6.0	(4.0‐8.0) MW,	P	=	0.45
Education Years 13	(12.5‐18.0) 15	(12.0‐17.8) MW,	P	=	0.83
Employment Working 13	(50) 54	(69.2) χ2	(1)	=	3.1,	P	=	0.08
Smoking Current 3	(11.5) 3	(3.8) χ2	(2)	=	3.9,	P	=	0.14
Ex 7	(26.9) 13	(16.7)
Never 16	(61.5) 62	(79.5)
Relationships In a relationship 16	(61.5) 56	(71.8) χ2	(1)	=	0.96,	P	=	0.33
Lives	alone 3	(11.5) 11	(14.1) FET,	P	=	1.0
ENRICHD 21.0	(15.8‐23.3) 27.5	(24.0‐29.3) MW,	P	<	0.0005
IBD	characteristics
Disease type Crohn's 15	(57.7) 40	(51.3) χ2	(2)	=	1.17,	P	=	0.56
UC 10	(38.5) 37	(47.4)
IBD‐U 1	(3.8) 1	(1.3)
Disease duration Years 5.9	(1.0‐14.7) 10.1	(4.3‐16.0) MW,	P	=	0.054
Age	at	diagnosis Years 29.6	(20.9‐47.0) 33.0	(24.3‐47.6) MW,	P	=	0.45
Disease activity Active	disease 13	(50) 17	(21.8) χ2	(1)	=	7.4,	P	=	0.007
Crohn's	disease	montreal	
classification
A1:	Age	<	17 2	(13.3) 4	(10.0) χ2	(2)	=	0.23,	P	=	0.89
A2:	17‐40 8	(53.3) 24	(60.0)
A3:	>40 5	(33.3) 12	(30.0)
L1:	Ileal 7	(46.7) 13	(32.5) χ2	(2)	=	1.05,	P	=	0.59
L2:	Colonic 3	(20.0) 12	(30.0)
L3:	Ileocolonic 5	(33.3) 15	(37.5)
+	L4:	Upper	GI 5	(33.3) 4	(10.0) FET,	P	=	0.095
B1:	Inflammatory 9	(60.0) 24	(60.0) χ2	(2)	=	0.17,	P	=	0.92
B2:	Stricturing 5	(33.3) 12	(30.0)
B3:	Penetrating 1	(6.7) 4	(10.0)
+	p:	Perianal 2	(13.3) 6	(15.0) χ2	(1)	=	0.02,	P	=	1.0
UC	montreal	classification E1:	Proctitis 4	(36.4) 4	(10.5) χ2	(2)	=	4.27,	P	=	0.12
E2:	Distal	colitis 3	(27.3) 17	(44.7)
E3:	Total	colitis 4	(36.4) 17	(44.7)
Medications 5	ASA 9	(34.6) 22	(28.2) χ2	(1)	=	0.38,	P	=	0.54
Corticosteroids 3	(11.5) 4	(5.1) FET,	P	=	0.36
Thiopurine 7	(26.9) 32	(41.0) χ2	(1)	=	1.66,	P	=	0.20
Methotrexate 1	(3.8) 3	(3.8) FET,	P	=	1.0
Anti‐TNF 3	(11.5) 33	(42.3) χ2	(1)	=	8.2,	P	=	0.004
Vedolizumab 6	(23.1) 13	(16.7) FET,	P	=	0.56
Ustekinumab 1	(3.8) 1	(1.3) FET,	P	=	0.44
Prior surgeries None 20	(76.9) 64	(82.1) χ2	(4)	=	2.9,	P	=	0.57





Right hemicolectomy 0	(0.0) 1	(1.3)
(Continues)











must	be	 regarded	as	preliminary,	 since	spurious	and	 inflated	asso‐
ciations may occur.48	Also,	since	conventional	symptom	scores	are	
heavily	weighted	by	quality	of	life	and	well‐being	domains	that	can	
be	 influenced	directly	by	depression,	use	of	 such	scores	 to	assess	
IBD	activity	risks	inflating	the	apparent	association	between	IBD	ac‐
tivity	and	depression.	To	avoid	this,	we	used	the	opinions	of	expert	





some	 confirmation	 of	 the	 validity	 of	 our	 IBD	 activity	 assessment	
method,	we	acknowledge	that	such	an	assessment	is	fundamentally	
subjective	 and	 therefore	 vulnerable	 to	 bias.Future	 studies	 should	
consider	using	more	valid	and	reliable	measures	of	IBD	activity	such	
as	fecal	calprotectin.
We	 interpret	 our	 findings	 as	 confirming	 that	 depression	 is	
common	in	hospital	outpatients	with	IBD,	and	that	having	active	
IBD	and	lacking	of	social	support	were	the	strongest	predictors	of	
Characteristic Depressed (N = 26) Non‐depressed (N = 78) Comparison
Baseline	laboratory	indices Haemoglobin	(g/L) 130.5	(117.8‐143.0) 134.5	(127.8‐143.5) MW,	P	=	0.18












SIBDQ	subscales Systemic 3.5	(2.4‐4.1) 4.5	(3.5‐5.5) MW,	P	<	0.0005
Social 5.0	(3.5‐5.6) 6.5	(5.0‐7.0) MW,	P	<	0.0005
Bowel 4.3	(3.5‐5.3) 5.7	(4.7‐6.3) MW,	P	<	0.0005
Emotional 3.3	(2.9‐3.7) 5.3	(4.3‐6.3) MW,	P	<	0.0005
Total	SIBDQ 4.0	(3.3‐4.6) 5.4	(4.6‐6.1) MW,	P	<	0.0005
EQ‐5D	VAS 62.5	(43.8‐70.0) 80.0	(70.0‐85.3) MW,	P	<	0.0005
EQ‐5D	index	value 0.72	(0.53‐0.76) 0.88	(0.74‐1.00) MW,	P	<	0.0005
Psychological characteristics
PHQ‐9 13.0	(12.0‐16.0) 5.0	(2.0‐6.3) MW,	P	<	0.0005
GAD‐7 9.0	(6.0‐12.0) 2.0	(0.0‐5.250 MW,	P	<	0.0005
Recent	Life	stresses Yes 22	(84.6) 37	(47.4) χ2	(1)	=	11.0,	P	=	0.001
Cognitive	assessments
Emotional	recognition 2.5	(−25.0	to	15.0) 15.0	(0.0‐35.0) MW,	P	=	0.002
Emotional	memory −10.0	(−30.0	to	0.0) −20.0	(−30.0	to	0.0) MW,	P	=	0.72
Reward and punishment processing
Learning	rate	Win	(n	=	43a) 0.05	(0.03‐0.21) 0.12	(0.02‐0.56) MW,	P	=	0.69
Temperature	Win	(n	=	43a) 0.14	(0.03‐0.36) 0.19	(0.02‐0.48) MW,	P	=	0.71
Learning	rate	Loss	(n	=	43a) 0.30	(0.11‐0.64) 0.20	(0.02‐0.53) MW,	P	=	0.34





T A B  L  E  2  
(Continued)
depression.	This	 finding	 is	 consistent	with	our	 research	 in	 rheu‐
matoid	 arthritis,	 which	 showed	 that	 depression	was	more	 likely	
among	people	who	experienced	life	difficulties	in	both	disease‐re‐
lated	and	non‐disease	related	domains.49 Due to our small popula‐
tion	size	and	the	loss	of	statistical	power	due	to	shifting	from	the	






Whilst	 depression	was	 associated	with	 clinical	 disease	 activ‐
ity,	we	did	not	find	that	depression	was	associated	with	hs‐	C‐re‐




mation,	 such	 as	 corticosteroids	 and	 TNF‐alpha	 inhibitors,	 which	
could	have	moderated	the	association	between	inflammation	and	
depression.50‐52	 Common	 use	 of	 such	 powerful	 anti‐inflamma‐
tory	 drugs	 in	 clinical	 populations	 could	mean	 that	 findings	 from	
research	into	acute	inflammation	in	healthy	individuals	performed	
in	 laboratory	 settings	 or	 using	 population‐based	 observational	




tion.	 Furthermore,	 exclusion	 of	 IBD	 sufferers	 with	 most	 severe	
depression	and	most	severe	IBD	may	have	weakened	associations	
that	would	have	otherwise	been	apparent	if	people	with	more	se‐












the	development	 and	maintenance	of	depression	 and,	 in	particular,	











derlying depression. Prospective study design will enable stronger 
causal	inferences	to	be	drawn	if	the	nature	of	the	temporal	relation‐





ity that psychological interventions targeting emotional recognition 
biases	among	people	with	IBD,	could	be	used	to	treat	or	even	prevent	
depression	in	high	risk	individuals,	such	as	those	with	active	IBD,	and	
thereby possibly improve medical as well as psychological outcomes.
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